^
    2d
    Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=4, Terminated, Jennifer Lee Caswell-Jin | Phase classification: P1b --> P1
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
    3d
    Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive/HER2-negative breast cancer. (PubMed, Front Oncol)
    In HR+/HER2- breast cancer, tumors with lower HER2 mRNA expression exhibit higher lymphocytic infiltration, suggesting the presence of a distinct immunologically active subset. Oncotype DX single gene scores, particularly HER2, may provide information beyond recurrence risk prediction and help identify patients who may benefit from immune-modulating therapeutic strategies.
    Journal • Tumor-infiltrating lymphocyte
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 expression • EGFR positive • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    3d
    Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review. (PubMed, Transl Breast Cancer Res)
    Three drugs of the class, abemaciclib, palbociclib and ribociclib, are currently approved in partially overlapping indications. A prominent downstream target of E2F that is repeatedly discussed in several studies is cyclin E. Key resistance mechanisms interfering with CDK4/6 inhibitor efficacy have been identified but are not yet used clinically. Diverse resistance mechanisms observed in individual cases would require individualized approaches to re-sensitize cancer cells and patients to cell cycle inhibition.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • EGFR positive • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
    4d
    The Frequency of PD-L1 Marker Expression in ER Positive, PR Positive, HER2 Negative Invasive Breast Carcinomas, and Its Correlation with Clinicopathological Factors Affecting Prognosis. (PubMed, Adv Biomed Res)
    Tumor subtype, tumor size, and axillary lymph node status showed no significant difference between the two groups (P value > 0.05). According to the results of this study, there is no relationship between the PD-L1 expression and well-known clinicopathological prognostic factors in ER-positive, PR-positive, and HER2-negative invasive breast carcinomas.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • ER positive • HER-2 negative • PD-L1 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    4d
    ESPRESSOBREAST: Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers (clinicaltrials.gov)
    P=N/A, N=1050, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 overexpression • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 positive + HER-2 overexpression
    5d
    FWD1802-001C: A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. (clinicaltrials.gov)
    P1/2, N=99, Recruiting, Forward Pharmaceuticals Co., Ltd. | Phase classification: P1 --> P1/2 | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Nov 2025 --> Mar 2026
    Phase classification • Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ESR1 mutation • ER positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    5d
    Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management (clinicaltrials.gov)
    P=N/A, N=18, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    6d
    CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer. (clinicaltrials.gov)
    P=N/A, N=61, Not yet recruiting, St. Antonius Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    9d
    Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (clinicaltrials.gov)
    P3, N=1978, Not yet recruiting, National Cancer Institute (NCI)
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • letrozole • anastrozole • exemestane
    10d
    PRELUDE: A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, National and Kapodistrian University of Athens
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    EndoPredict®
    10d
    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (clinicaltrials.gov)
    P3, N=1156, Suspended, Alliance for Clinical Trials in Oncology | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • anastrozole • exemestane
    10d
    A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    cyclophosphamide • decitabine • Proleukin (aldesleukin)